These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10306 related articles for article (PubMed ID: 15715049)

  • 21. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
    Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
    Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
    Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
    Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunology and canine malignant melanoma: A comparative review.
    Atherton MJ; Morris JS; McDermott MR; Lichty BD
    Vet Immunol Immunopathol; 2016 Jan; 169():15-26. PubMed ID: 26827834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy.
    Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH
    Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo.
    Cochlovius B; Linnebacher M; Zewe-Welschof M; Zöller M
    Int J Cancer; 1999 Nov; 83(4):547-54. PubMed ID: 10508493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.
    von Euler H; Sadeghi A; Carlsson B; Rivera P; Loskog A; Segall T; Korsgren O; Tötterman TH
    J Immunother; 2008 May; 31(4):377-84. PubMed ID: 18391758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
    Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
    Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.
    Berard F; Blanco P; Davoust J; Neidhart-Berard EM; Nouri-Shirazi M; Taquet N; Rimoldi D; Cerottini JC; Banchereau J; Palucka AK
    J Exp Med; 2000 Dec; 192(11):1535-44. PubMed ID: 11104796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.
    Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J
    J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
    de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
    J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
    Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
    Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 516.